Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
LEXICON PHARMACEUTICALS, INC. issued 184,365.8 shares of its Series B Convertible Preferred Stock of preferred stock to affiliate of Invus for $65 per share.
- Security
- preferred stock
- Shares
- 184,365.8 shares of its Series B Convertible Preferred Stock
- Purchaser
- affiliate of Invus
- Consideration
- $65 per share
Exact text from the filing
on January 29, 2026, the Company entered into a Preferred Stock Purchase Agreement with an affiliate of Invus (the “ Preferred Private Placement Purchaser ” and, such agreement, the “ Preferred Purchase Agreement ”), pursuant to which the Company agreed to (i) sell 184,365.8 shares of its Series B Convertible Preferred Stock, par value $0.01 per share (the “ Preferred Stock ”), at a price of $65 per share in a private placement in partial satisfaction of the Invus Entities’ preemptive right under the Certificate of Incorporation
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
LEXICON PHARMACEUTICALS, INC. issued 22,400,000 shares of Common Stock of common stock to Artal Participations S.à r.l., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Invus US Partners LLC, Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, L.P., Siren, LLC, Ulys, L.L.C. and Mr. Raymond Debbane for $29.12 million.
- Security
- common stock
- Shares
- 22,400,000 shares of Common Stock
- Purchaser
- Artal Participations S.à r.l., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Invus US Partners LLC, Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, L.P., Siren, LLC, Ulys, L.L.C. and Mr. Raymond Debbane
- Consideration
- $29.12 million
Exact text from the filing
and Restated Certificate of Incorporation (the “ Certificate of Incorporation ”). The total purchase price of the Common Stock purchased by the Private Placement Purchasers was $29.12 million. The Common Stock Purchase Agreement incorporates the representations and warranties and covenants made by the Company in the Underwriting Agreement for the benefit of the
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
LEXICON PHARMACEUTICALS, INC.: Filing of Certificate of Designations for Series B Convertible Preferred Stock, including terms for automatic conversion conditioned on stockholder approval of a new charter increasing authorized common shares (effective 2026-02-02).
- Change
- charter amendment
- Effective
- 2026-02-02
Exact text from the filing
On February 2, 2026, in connection with the Preferred Private Placement, the Company filed with the Secretary of State of the State of Delaware to be effective upon filing the Certificate of Designations of Series B Convertible Preferred Stock of the Company (the “ Certificate of Designations ”), in the form approved and adopted by the board of directors of the Company, which sets forth the terms of the Preferred Stock.
View on SEC.gov